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Long-lived plasma cells, residing primarily in the bone marrow, continuously secrete antibody 
and provide an important component of humoral memory. However, when such cells secrete 
autoantibodies or become transformed, they can be pathogenic. We have shown recently 
that the transcriptional repressor B lymphocyte–induced maturation protein 1 (Blimp-1) is 
required for the formation of plasma cells. To determine what role Blimp-1 might play in 
maintenance of plasma cells, we generated mice in which the gene encoding Blimp-1 could 
be deleted in an inducible manner. Deletion of Blimp-1 either in vitro or in vivo leads to 
loss of previously formed B220
 
LO
 
CD138
 
HI
 
 plasma cells. Using BrdU incorporation, we confirmed 
that Blimp-1 is required for the maintenance of nondividing, long-lived plasma cells in the 
bone marrow. Blimp-1 is also required for long-term maintenance of antigen-specific 
immunoglobulin in serum. Thus Blimp-1 is required not only for the formation but also for 
the maintenance of long-lived plasma cells. This finding provides the possibility of new drug 
design strategies for autoimmunity and multiple myeloma focused on blocking Blimp-1 
expression or activity.
 
Upon initial encounter with pathogens, B
cells can differentiate into two types of cells
that provide humoral memory as follows: (a)
memory cells that differentiate into Ig-secret-
ing plasma cells upon secondary antigenic
challenge and (b) plasma cells that survive in
the bone marrow, continuously secreting Ig
(1). Long-lived plasma cells in the marrow
are germinal center–experienced cells (2)
that survive for months to years (3) in the ab-
sence of antigen (4) or cell division (5).
These cells reside in a limited number of
niches, primarily in the bone marrow, that
provide them with survival signals (6). The
antibodies that these long-lived plasma cells
secrete provide protection for future encoun-
ters with the pathogens that led to their forma-
tion. Although long-lived plasma cells are crit-
ical for humoral memory, they can also be
pathogenic when they express autoantibodies
in diseases such as lupus erythematosus (7)
or become transformed in multiple my-
eloma. Treatments designed to target B line-
age cells, such as radiation, prednisone, cy-
clophosphamide, and anti-CD20 antibodies
(8), do not eliminate nondividing long-lived
plasma cells. Thus, in lupus and multiple
myeloma, these treatments often do not lead
to resolution of disease.
Despite the physiological and pathological
significance of long-lived plasma cells, little
is known about their maintenance. There is
increased  understanding, however, of how
plasma cell formation is regulated (6). B lympho-
cyte–induced maturation protein-1 (Blimp-1)
is a transcriptional repressor that is found both
necessary (9) and sufficient (10) for plasma
cell differentiation. Blimp-1 is called a master
regulator of plasma cell differentiation because
it directly represses transcription factors that,
in turn, regulate several important gene programs
(11). Blimp-1 represses c-
 
myc
 
 and other genes
involved in cell cycle progression and cell
division (11, 12). Blimp-1 represses Bcl-6
(11), a key germinal center factor, and blocks
other germinal center activities. Finally,
Blimp-1 represses Pax-5 (13), which is required
for B cell identity, germinal center function,
and repression of XBP-1 (14); J chain; and Ig
heavy and light chain transcription. By relieving
Pax-5–dependent repression of these genes,
Blimp-1 drives plasmacytic differentiation
and Ig secretion (9, 15). Thus, Blimp-1 both
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induces plasmacytic differentiation and inhibits the alternate
mature B cell fate.
Blimp-1 requires association with Groucho and histone
deacetylases (16, 17) and the G9a histone methyltransferase
(18) for its repressive activity. Nucleosomes near functional
Blimp-1 binding sites have deacetylated H3 lysines in a plas-
macytoma expressing endogenous Blimp-1 (13) and meth-
ylated H3 lysine 9 in cells ectopically expressing Blimp-1 (18).
Although histone acetylation/deacetylation is known to be
dynamic, histone methylation appears to be more stable.
Blimp-1–dependent chromatin modifications might be sta-
ble because terminally differentiated plasma cells do not di-
vide. However, Blimp-1 is expressed in bone marrow plasma
cells and multiple myeloma cells, suggesting its continued
presence could be required (11).
Here, using a mouse where the gene encoding Blimp-1
can be inducibly deleted, we show that Blimp-1 is required
not only for the formation of plasma cells, but also for their
maintenance as long-lived Ig-secreting cells in the bone
marrow. This sheds light on the biology of these important
cells and challenges the idea that plasma cells have a stable
gene expression program. Additionally, the discovery that
Blimp-1 is required to maintain long-lived plasma cells sug-
gests that interfering with Blimp-1 may provide a new ratio-
nale for designing drugs to treat autoimmune diseases or
multiple myeloma.
 
RESULTS AND DISCUSSION
Blimp-1 is required for plasma cell maintenance in vitro
 
To determine if Blimp-1 is required for maintenance of
plasma cells after they form, we created mice in which de-
letion of 
 
prdm1
 
, encoding Blimp-1, could be regulated
by treatment with tamoxifen. 
 
Prdm1
 
Flox/Flox
 
 mice (9) were
crossed with mice in which cDNA encoding Cre recombi-
nase fused to a mutated estrogen receptor ligand binding
domain (ERCre) was inserted into the ROSA 26 gene.
Short-lived plasma cells can be generated in vitro by
treating splenocytes with the polyclonal activator, LPS. We
harvested splenocytes from 
 
ERCre
 
 
 
prdm1
 
F/F
 
 and control
mice and cultured them in LPS for 3 d. After 3 d, 98%
of cells were of the B cell lineage (B220
 
 
 
) and 12–20%
were CD138
 
HI
 
 plasma cells in both cultures (unpublished
data). We treated the cells with either 4-hydroxytamoxifen
(4OHT) or vehicle for an additional 4 d. At the end of the
treatment, Blimp-1 was detected by immunoblotting in con-
trol cultures, but not in 
 
ERCre
 
 
 
prdm1
 
F/F
 
 cultures treated
with 4OHT (Fig. 1 A), indicating that deletion in vitro was
efficient and Blimp-1 was no longer present. After 7 d, con-
trol cultures treated with 4OHT had a 30% reduction in the
frequency of CD138
 
HI
 
 plasma cells compared with vehicle
treated cultures, whereas 
 
ERCre
 
 
 
prdm1
 
F/F
 
 cultures treated
with 4OHT showed 90% reduction in plasma cell frequency
compared with vehicle-treated cultures (Fig. 1 B). A similar
Figure 1. Loss of Blimp-1 in vitro. Splenocytes were treated with LPS 
for 3 d in vitro followed by 4 d of 4-hydroxytamoxifen (4OHT) or sham 
treatment. (A) Western blot for Blimp-1 and actin protein in ERCre prdm1F/F 
and control cultures treated with 4OHT and sham. (B) CD138 vs. B220 staining 
of splenocyte cultures. (left) Control; (right) ERCre prdm1F/F cultures; (top) 
sham; (bottom) 4OHT treated. The frequency of gated CD138HI plasma cells 
is indicated. Depicted results are representative of five experiments. 
(C) Kinetics of plasma cell disappearance after 4OHT treatment. (left) The 
percent of total B220LOCD138HI plasma cells in control (solid square) and 
ERCre prdm1F/F (open square) cultures for 4 d after 4OHT treatment. (right) 
The percent of CFSEHI plasma cells in these cultures. (D) IgM-secreting cells 
as assessed by ELISPOT analysis for ERCre prdm1F/F and control cultures 
treated with 4OHT and sham. The y axis represents number of IgM-secreting 
cells per 2,000 cells. C and D are representative of two experiments. 
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difference was observed in multiple experiments. In one ex-
periment, B cells in LPS culture were labeled with a divi-
sion-tracking dye at the time 4OHT was added, to distin-
guish newly forming plasma cells (B220
 
LO
 
CD138
 
HI
 
CSFE
 
LO/
 
 
 
)
from nondividing, previously formed plasma cells (B220
 
LO
 
CD138
 
HI
 
CSFE
 
HI
 
) (Fig. 1 C). After 3–4 d of 4OHT treat-
ment, both total and CSFE
 
HI
 
 plasma cells disappeared more
rapidly and to a greater overall extent in cultures of
 
ERCre
 
 
 
prdm1
 
F/F
 
 B cells than in controls. Consistent with
this, ELISPOT analyses showed a substantial number of IgM
secreting cells in control cultures at the end of the culture
period, but in the 
 
ERCre
 
 
 
prdm1
 
F/F
 
 cultures treated with
4OHT, the number of IgM-secreting cells was greatly re-
duced (Fig. 1 D). Thus, Blimp-1 is required to maintain
previously formed plasma cells in vitro.
 
Blimp-1 is required for plasma cell maintenance in vivo
 
We expanded these studies to long-lived plasma cells in the
bone marrow of mice. 3–4 wk after intraperitoneal injection
of mice with tamoxifen, deletion of 
 
prdm1
 
 in bone marrow
cells was assessed by Southern blotting. In 
 
ERCre
 
 
 
prdm1
 
F/F
 
mice, deletion of the floxed allele was very efficient (Fig. 2).
Because Blimp-1 mRNA and protein have half lives of
 
 
 
2 and 4 h, respectively (unpublished data), Blimp-1 pro-
tein disappears soon after gene deletion. The presence of
B220
 
LO
 
CD138
 
HI
 
 plasma cells was assessed by flow cytome-
try. 
 
ERCre
 
 
 
prdm1
 
F/F
 
 mice had a more than fourfold reduc-
tion in the frequency of plasma cells in the bone marrow
compared with control mice (not depicted), suggesting that
Blimp-1 is required to maintain these cells. Both 
 
ERCre
 
 
 
prdm1
 
F/
 
 
 
 and 
 
ERCre
 
 
 
prdm1
 
F/F
 
 mice were used as controls in
this and other experiments and no differences were observed
between them.
 
Blimp-1 is required for the maintenance of long-lived, 
nondividing plasma cells
 
Because Blimp-1 is known to be required for the differentia-
tion of B cells into plasma cells and because our initial studies
did not fully distinguish loss of previously formed plasma cells
from inability to form new plasma cells, we studied this fur-
ther. Mice were fed BrdU in drinking water from the time of
tamoxifen treatment until bone marrow harvest. B cells (19)
and plasma cell precursors (20) proliferate during plasmacytic
differentiation so that plasma cells formed after tamoxifen
treatment would be BrdU
 
 
 
, whereas previously formed,
long-lived plasma cells would be BrdU
 
 
 
. The ratio of
BrdU
 
 
 
/BrdU
 
 
 
 plasma cells shows the distribution of these
two populations. In bone marrow 3–4 wk after tamoxifen
treatment (Fig. 3 A), we observed the anticipated decrease
B220
 
LO
 
CD138
 
HI
 
BrdU
 
 
 
 plasma cells, confirming our previous
report that plasma cell formation requires Blimp-1 (11). In ad-
dition, we observed a fourfold decrease in BrdU
 
 
 
 plasma cells
(Fig. 3, A and B). This decrease shows that the continued
presence of long-lived, nondividing B220
 
LO
 
CD138
 
HI
 
 plasma
cells in the bone marrow requires Blimp-1.
 
Blimp-1 is required for long-term maintenance of serum Ig
 
We wished to determine if Ig secretion was affected when
 
prdm1
 
 was deleted in long-lived plasma cells, as suggested by
the decrease in B220
 
LO
 
CD138
 
HI
 
 cells. 
 
ERCre
 
 
 
prdm1
 
F/F
 
 and
control mice were immunized with NP-KLH. 6 wk after
immunization, when both the early and the post–germinal
center plasma cell responses had subsided, serum was har-
vested before mice were treated with tamoxifen. 5 wk after
tamoxifen treatment (11 wk postimmunization), serum was
again harvested. When final NP-specific IgG1 levels were
compared with the initial levels before tamoxifen treatment,
control mice had 35% remaining, but 
 
ERCre
 
 
 
prdm1
 
F/F
 
 mice
had only 8% remaining, a fourfold lower amount (Fig. 4 A).
Figure 2. Loss of Blimp-1 in vivo. Southern blots of DNA from total 
bone marrow harvested 3.5 wk after tamoxifen treatment. Bands for 
deleted, wild type, and floxed prdm1 are indicated.
Figure 3. Loss of long-lived bone marrow plasma cells after 
deletion of prdm1. (A) Plots of CD138 vs. BrdU for bone marrow from 
ERCre prdm1F/F and control mice that received tamoxifen 3–4 wk previously 
and were fed BrdU from the time of tamoxifen treatment until harvest. 
Boxes represent CD138HI plasma cells that did not incorporate BrdU. 
(B) Total BrdU  B220LOCD138HI plasma cells after tamoxifen treatment 
(averages and SEM for three ERCre prdm1F/F and three control mice). Gray 
bars represent control and white bars represent ERCre prdm1F/F. 
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Thus, we conclude that Blimp-1 is required for continued Ig
secretion by long-lived plasma cells. Decreased serum Ig is
also consistent with cell loss rather than egress of Ig-secreting
cells from the bone marrow to other peripheral sites.
When 
 
ERCre
 
 
 
prdm1
 
F/F
 
 mice are treated with tamoxifen,
 
prdm1
 
 is deleted in all cells due to the ubiquitous expression
of ERCre. Because Blimp-1 is expressed in epithelial cells
(unpublished data), we reasoned that the requirement for
Blimp-1 could reside in bone marrow stromal cells. To test
this possibility, we designed an adoptive transfer experiment
in which bone marrow cells from immunized mice were
transferred to naive mice in which normal bone marrow
stroma was present. 
 
ERCre
 
 
 
prdm1
 
F/F
 
 and control mice were
immunized and later boosted with NP-KLH. 7–9 wk after
secondary immunization, bone marrow was transferred to
sublethally irradiated naive hosts. After allowing levels of
NP-specific serum Ig to stabilize in the recipients, tamoxifen
was administered and serum was harvested 3, 5, and 10 wk
later to assess levels of NP-specific IgG1 by ELISA. Although
NP-specific IgG1 decreased over time in the mice with con-
trol bone marrow, NP-specific IgG1 decreased to a substan-
tially greater degree in mice with 
 
ERCre
 
 
 
prdm1
 
F/F
 
 bone
marrow (Fig. 4 B). 10 wk posttamoxifen, NP-specific IgG1
had fallen 66-fold more in mice that received 
 
ERCre
 
 
 
prdm1
 
F/F
 
 bone marrow compared with those receiving con-
trol marrow (control 59% of initial Ig level vs. 
 
ERCre
 
 
 
prdm1
 
F/F
 
 0.9% of initial Ig level). Thus, the requirement for
Blimp-1 does not reside in the stromal cells but appears to be
intrinsic to the transferred plasma cells. This conclusion is
also consistent with the B cell intrinsic requirement for
Blimp-1 to maintain plasma cells in vitro (Fig. 1).
 
Blimp-1 and plasma cell maintenance
 
Although much is known about genes involved in the differ-
entiation of B cells to plasma cells (6), there is less information
about genes required for maintenance of plasma cells in the
bone marrow. XBP-1, a transcriptional activator required for
plasma cell formation (21), is required continuously for sur-
vival of myeloma cells because treatment with a proteasome
inhibitor, which reduces levels of activated XBP-1, causes
apoptosis due to ER stress (22). XBP-1 is probably required
for maintenance of long-lived plasma cells, but this has not
been tested directly. Blimp-1 is required for XBP-1 induc-
tion during plasmacytic differentiation (9, 15) and lack of
XBP-1 may be an important component in the requirement
for Blimp-1 shown in this study. Aiolos, an Ikaros family
member, is required for long-lived plasma cells to appear in
the bone marrow, but it is unclear if it affects formation,
migration, and/or maintenance of these cells (23).
Mice lacking BCMA, a receptor for the TNF super-
family factors BAFF and APRIL, have reduced bone mar-
row plasma cells, suggesting that BAFF and/or APRIL are
necessary for survival of these cells (24). However, BAFF
enhances survival of human plasmablasts, but not plasma
cells (25). Interestingly, APRIL binds not only to BCMA
and TACI receptors, but also to the proteoglycan CD138,
which is highly expressed on plasma cells (26). Thus,
APRIL may be an important survival factor for bone mar-
row plasma cells. IL-6 supports the survival of isolated bone
marrow plasma cells and is a survival factor for myeloma
cells; however, IL-6
 
 
 
/
 
 
 
 mice have no abnormalities of
plasma cell maintenance in vivo (27), suggesting other sur-
vival factors can compensate for its absence. In other set-
tings, STAT3 (28) (which is activated by IL-6), NF-
 
 
 
B
(unpublished data), and AP-1 (29) (when activated by toll-
like receptors and possibly TNF family receptors) induce
 
prdm1
 
 transcription. Thus, an important function of sur-
vival signals from the bone marrow stroma to plasma cells
may be activation of transcription factors required for
transcription of 
 
prdm1
 
.
Our data have interesting implications for the molecular
mechanisms by which Blimp-1 represses target gene transcrip-
tion. As discussed before, Blimp-1’s repressive function in-
volves both histone deacetylation and histone methylation, the
latter being thought to be a relatively stable chromatin modifi-
cation. The results reported here suggest that the covalent
chromatin modifications associated with Blimp-1–dependent
repression are not stable, even in the absence of cell division,
and show that the continuous presence of Blimp-1 is required
to keep its target genes repressed. Such a mechanism would fit
with a model where survival signals drive continued Blimp-1
Figure 4. Loss of antigen-specific Ig after deletion of prdm1. 
(A) 6 wk after immunization with NP-KLH, ERCre prdm1F/F and control 
mice were treated with tamoxifen. The levels of NP-specific serum IgG1 at 
5 wk after tamoxifen treatment divided by the levels immediately before 
tamoxifen treatment for three ERCre prdm1F/F and control mice were 
averaged (with SEM) and graphed. Gray bars represent control and white 
bars represent ERCre prdm1F/F. (B) Bone marrow from ERCre prdm1F/F or 
control NP-KLH immunized mice was transferred to naive hosts. After 
engraftment, tamoxifen was administered. Serum was harvested on the 
day of the first tamoxifen dose and at later dates. Graph depicts the fraction 
of posttamoxifen NP-specific serum IgG1 at 3, 5, and 10 wk divided by 
pretamoxifen NP-specific serum IgG1 (averages with SEM for three 
ERCre prdm1F/F and control donors). Closed circles represent control 
and open circles represent ERCre prdm1F/F.JEM VOL. 202, December 5, 2005 1475
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expression in plasma cells that inhabit specific survival niches.
Eventual loss of Blimp-1 in plasma cells that are ejected from
their bone marrow niches by competitors or never reach such
niches could be the physiological basis for plasma cell loss.
Our data do not distinguish whether long-lived plasma
cells die or dedifferentiate upon the loss of Blimp-1. The re-
quirement for XBP-1 in the survival of myeloma cells and
the role of Blimp-1 in inducing XBP-1 suggest that plasma
cells lacking Blimp-1 might die due to ER stress secondary
to absence of XBP-1. However, a recent study has shown
that the plasma cell phenotype of a myeloma line can be
reversed by forced coexpression of the germinal center
proteins MTA3 and Bcl-6 (30). In these experiments, de-
differentiation included reduction of Blimp-1 and XBP-1
mRNAs. Because Blimp-1 represses Bcl-6 (11), deletion of
prdm1 could derepress Bcl-6, causing dedifferentiation with
loss of Ig secretion and CD138 expression, which are the
two plasma cell phenotypes we monitored.
Long-lived plasma cells can be pathogenic in autoim-
mune diseases such as systemic lupus erythematosus (7),
where autoantibodies contribute to pathology, and in multi-
ple myeloma, where CD138  tumor cells in the bone mar-
row apparently represent the transformed counterparts of
long-lived plasma cells. However, as discussed before, long-
lived plasma cells are resistant to the treatments often used in
these diseases. Thus, regardless of the ultimate fate of plasma
cells lacking Blimp-1, our data show that targeting Blimp-1
or its regulators provides a novel approach in drug design
strategies to eliminate long-lived plasma cells or their trans-
formed counterparts in bone marrow.
MATERIALS AND METHODS
Mice. Prdm1F/F and prdm1F/  mice were crossed with ERCre mice to gen-
erate controls (ERCre prdm1F/ , ERCre prdm1F/F, or ERCre prdm1F/ )
and experimental (ERCre prdm1F/F or ERCre prdm1F/ ) mice. No differ-
ences were observed in control or experimental mice with varying geno-
types; in the text, experimental mice are labeled ERCre prdm1F/F for
simplicity. The ERCre mice were a gift from T. Ludwig (Columbia Uni-
versity, New York, NY). All procedures with mice were approved by the
Institutional Animal Care and Use Committee of Columbia University.
In vitro cultures. Splenocytes were cultured with LPS as previously de-
scribed (11) and were treated with 100 nM 4-hydroxytamoxifen in ethanol or
sham treated (ethanol or no treatment) on day 3 of culture. Splenocytes treated
with CFSE were prewashed with PBS and incubated with 25 nM of CFDA SE
dye (GE Healthcare) following the manufacturer’s instructions. Aliquots of cells
were harvested daily for 4 d and stained for FACS (see Flow cytometry section),
plated for ELISPOT analysis, or lysed for Western blot analysis. The methods
for the latter two experiments were described previously (11).
In vivo tamoxifen treatment. Mice were injected intraperitoneally on
three consecutive days with 0.5 ml of 10 mg/ml tamoxifen in sunflower
seed oil.
Immunization. Mice were immunized i.p. and later boosted i.p. in ap-
propriate experiments, with 400  g NP-KLH in Ribi adjuvant (Corixa).
BrdU feeding. Mice were fed drinking water with 1.0 mg/ml BrdU start-
ing at the time of tamoxifen injection until bone marrow harvest 3–4 wk
later. Water was changed every other day and protected from light.
Bone marrow transfer. Recipient C57B/6 or B6/SJL congenic mice
were irradiated at 680 rad and rested for 1 d. BM was harvested from con-
trol and ERCre prdm1F/F mice 7–9 wk after NP-KLH boost and 6.5–7.9  
106 total BM cells were transferred by tail vein injection to recipients. Mice
were fed water with Baytril for the duration of the experiment.
Southern blot. DNA was extracted from BM harvested from control and
ERCre prdm1F/F mice and Southern blotting was performed as described
previously (9). Wild type, floxed, and deleted prdm1 were detected as 15-,
13.5-, and 10-kb bands, respectively.
Flow cytometry. BM was harvested from control and ERCre prdm1F/F
mice 3–4 wk after tamoxifen treatment, red blood cells were lysed, and cells
were stained with  -CD138-PE (BD Biosciences) and  -B220-allophycocy-
anin or  -B220-FITC (eBioscience). The buffer for all antibody incubations
and washes was PBS with 1% BSA, 2% FCS, 0.03% NaN3, and 2 mM
EDTA. For BrdU experiments, after B220 and CD138 staining, cells were
washed, resuspended in ice-cold 0.15 M NaCl, and permeabilized with ice-
cold 100% ethanol. After washing, cells were fixed with 1% paraformalde-
hyde, washed, treated with DNase I (Sigma-Aldrich), and washed before
incubation with  -BrdU-allophycocyanin (GE Healthcare) for flow cytometry.
ELISA. Serum was harvested from mice at various times, processed and,
diluted to an appropriate range for ELISA analysis to detect NP-specific
IgG1 as described previously (9).
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